Selective Treatment According to Molecular Subtype of Prostate Cancer

NCT03696186 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Castration-resistant Prostate Cancer
Prostate Cancer Metastatic

Interventions

DRUG: Luminal type-1
DRUG: Luminal type-2
DRUG: Neuroendocrine type-1
DRUG: Neuroendocrine type-2
DRUG: Atypical type-1
DRUG: Atypical type-2

Sponsor

Tianjin Medical University Second Hospital